Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496080 · ClinicalTrials.gov registry record · NA
Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding
A NA study, sponsored by Ethicon.
- Terminated
- Registry status
- NA
- Development phase
- 87
- Enrollment target
NCT00496080: Clinical Trial NA study, sponsored by Ethicon.
NCT00496080 is a NA study that was terminated before completion, run by Ethicon. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496080, a NA study, was terminated before completion, sponsored by Ethicon.
- TERMINATED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of Doppler guided uterine artery occlusion (D-UAO) for the reduction of fibroid associated bleeding.
Primary Outcome
Number of participants without any subsequent surgical procedure intended to manage fibroid symptoms performed. Potential procedures included surgical hysterectomy or dilatation and curettage (D\&C) for treatment of menorrhagia; uterine artery embolization (UAE) or laparoscopic uterine artery occlusion; endometrial resection or ablation; myomectomy or myolysis.
Interventions
- DEVICE Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-10 |
| Phase | NA |
Why NCT00496080 stopped before completion
NCT00496080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Doppler-Guided Uterine Artery Occlusion Device (DUAO) is the first listed.
NCT00496080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00496080 about?
NCT00496080 is a clinical study titled "Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding". The objective of this study is to evaluate the safety and effectiveness of Doppler guided uterine artery occlusion (D-UAO) for the reduction of fibroid associated bleeding.
What is the current status of trial NCT00496080?
This trial is currently terminated. It is a NA study. The enrollment target is 87 participants. The study started on 2007-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00496080?
The interventions under investigation include: Doppler-Guided Uterine Artery Occlusion Device (DUAO) (DEVICE).
Who is sponsoring clinical trial NCT00496080?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00496080's enrollment target sits among peer trials
87 974th of 2000 higher than 1,025 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia